Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells

Abstract

Background: Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate the mechanisms underlying drug resistance in BL, we established drug-resistant BL cell lines: HS-Sultan/ADM (adriamycin-resistant), HS-Sultan/VCR (vincristineresistant), HS-Sultan/DEX (dexamethasone-resistant), and HS-Sultan/L-PAM (melphalan-resistant). Methods: Drug transporter and survival factor expression were investigated the using western blotting and real time polymerase chain reaction. Cell survival was analyzed by trypan blue dye exclusion method. Results: The established cell lines acquired cross-resistance to adriamycin, vincristine, dexamethasone, and melphalan and exhibited 50% inhibitory concentration values 106-, 40-, 81-, and 45-fold higher than the parental cell lines, respectively. We found that protein and mRNA expression of MDR1 and Survivin were higher in drug-resistant BL cells than in the parent cells. Treatment with verapamil, an MDR1 inhibitor, or Survivin siRNA alongside each anti-cancer drug suppressed the proliferation of all drug-resistant BL cells. Src kinase activity was higher in all resistant cell lines than the parental cells; suppressing Src with dasatinib restored drug sensitivity by reducing MDR1 and Survivin expression. Conclusions: MDR1 and Survivin upregulation are responsible for resistance to conventional drugs and dasatinib can restore drug sensitivity by reducing MDR1 and Survivin expression in drug-resistant BL cells. Src inhibitors could therefore be a novel treatment strategy for patients with drug resistant BL.

Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol

“…Although P-gp is overexpressed both in GC- resistant and sensitive pre-B ALL cells, its activity does not correlate with GC sensitivity ( 87 , 201 ). As it was demonstrated recently, inhibition of an upregulated MDR1 in a GC-resistant B-ALL sensitized cells to DEX ( 202 ).…”

Gambogenic Acid Inhibits Basal Autophagy of Drug-Resistant Hepatoma Cells and Improves Its Sensitivity to Adriamycin

“…25) ABCB1 (member of the ATP binding box B subfamily 1) belongs to the ABC protein family and is one of the most important mechanisms for MDR. 26) In a study of tumor specimens in patients with colorectal cancer, ABCB1 and LC3 (light chain 3) were positively correlated with the expression levels of Beclin1 and Rictor. Instead, there is a negative correlation between the expression levels of ABCB1 and Raptor (regulatory-binding protein of mammalian target of rapamycin (mTOR)).…”

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux

“…Second, the AKR1C3 single nucleotide polymorphism may influence the survival outcomes of patients receiving the CHOP regimen [ 69 ]. Finally, the role of ABC transporters in cancer responses to ANT-containing chemotherapy has been suggested in DLBCL [ 70 ], MCL [ 71 ], and Burkitt lymphoma [ 72 ]. In addition to the primary indication of BTK inhibitors in CLL and lymphomas, their efficacy has recently been demonstrated in AML and solid tumours [ 73 , 74 , 75 , 76 ].…”